Biovail, Anchen Pharmaceuticals Inc., GlaxoSmithKline, Impax, Teva Pharmaceuticals Industries Ltd., Watson neurology news

The parties settled litigation related to generic versions of BVF's depression drug Wellbutrin XL bupropion. BVF dismissed its suits against IPXL and WPI. The settlement allows TEVA, which launched a 300 mg dose of the generic last December under a deal with IPXL and Anchen, to exclusively market that product until June 13 and to exclusively market a 150 mg dose for 180 days after launch, which is expected in 2008. Last August, the U.S. District Court for the Central District of California ruled that Anchen did not infringe BVF's patent for the extended-release norepinephrine and dopamine reuptake inhibitor (see BioCentury, Aug. 7, 2006). ...